Five year follow-up results of a phase II trial in patients with late chronic phase (L-CP) chronic myeloid leukemia (CML) treated with imatinib who are refractory/intolerant of interferon-α

被引：11

作者：

Gambacorti, C

Talpaz, M

Sawyers, CL

Druker, BJ

Hochhaus, A

Schiffer, CA

Guilhot, F

Niederwieser, DW

Stone, RM

Goldman, JM

Mone, M

Krahnke, T

Gathmann, I

Kantarjian, HM

机构：

[1] Univ Milan Bicocca, Monza, Italy

[2] McGill Univ, Montreal, PQ, Canada

来源：

关键词：

D O I：

10.1182/blood.V106.11.1089.1089

中图分类号：

R5 [内科学];

学科分类号：

1002 ; 100201 ;

摘要：

1089

引用

页码：317A / 317A

页数：1